Catalyst
Monitor market uptake and physician adoption rates of the subcutaneous formulation, as well as competitive responses from other multiple myeloma therapies.
Humanexa recommends Monitor.
Date
July 11, 2026
Phase
N/A
Status
watch
Signal score
8.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.